If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options NEW YORK, S ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Faruq ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4][9]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements [6][8]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA, citing the same cGMP deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 [8]. Group 3: Company Background - Unicycive Therapeutics, Inc. is publicly traded on NASDAQ under the ticker UNCY [4]. - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - Unicycive Therapeutics is under investigation for possible securities fraud following a significant stock price decline after the FDA issued a Complete Response Letter for its New Drug Application [1][3][4] Company Summary - Unicycive Therapeutics, Inc. (NASDAQ: UNCY) has faced legal scrutiny as the Portnoy Law Firm has initiated an investigation into potential securities fraud and may file a class action on behalf of investors [1] - The company received a Complete Response Letter from the FDA regarding its New Drug Application for OLC, which is intended to treat hyperphosphatemia in patients with chronic kidney disease on dialysis [3] - The FDA's response was triggered by deficiencies found in a third-party manufacturing vendor during a cGMP inspection [3] Stock Performance - Following the FDA announcement, Unicycive's stock price fell by $2.03 per share, representing a decline of approximately 29.85%, closing at $4.77 per share on June 30, 2025 [4]

[Click here for information about joining the class action] On June 30, 2025, Unicycive release issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." The press release stated that "[a]fter submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicyc ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On June 30 ...

Core Points - Unicycive Therapeutics, Inc. announced that the U.S. FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for OLC, intended to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis [1] - Following the FDA's announcement, Unicycive's stock price experienced a decline [1] Company Overview - Holzer & Holzer, LLC is investigating whether Unicycive complied with federal securities laws in light of the recent FDA decision [1] - The law firm specializes in representing shareholders and investors in litigation, including shareholder class action and derivative litigation [3] - Holzer & Holzer has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]